Fenofibric Acid NDC 59651-217

NDC codes

FDA NDC Directory

Product NDC (as listed)59651-217Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59651-0217Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
59651-217-90	59651021790	90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (59651-217-90)Marketed from Jul 25, 2019

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Fenofibric Acid
Generic name (nonproprietary): fenofibric acid
Active ingredients: Fenofibric acid — 135 mg/1
Dosage form: Capsule, Delayed release
Route: Oral
Labeler: Aurobindo Pharma Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212598
Marketing start: Jul 25, 2019
Listing expires: Dec 31, 2026
Identifiers: Product ID 59651-217_21dc5a32-9e47-415c-8b55-f97c5e7b15e1SPL ID 21dc5a32-9e47-415c-8b55-f97c5e7b15e1SPL set ID 9ad201de-fa62-4c49-bc61-ee09b9ba434cRxCUI 828373, 828379UNII BGF9MN2HU1
Pharmacologic class: Peroxisome Proliferator Receptor alpha Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459651021790 followed by a unit qualifier and the quantity

Package 59651-0217-90. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 2, 2025.

Indications (excerpt from the label)

Fenofibric acid delayed-release capsules are indicated as adjunctive therapy to diet: to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL). to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. Limitations of Use Markedly elevated levels of serum TG (e.g., > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been determined [see Warnings and Precautions (5.7) ] . Fenofibrate did not reduce coronary heart disease morbidity and mortality in two l…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 212598

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 212598
Product	Strength	Form · route	Labeler	Product NDC
Fenofibric Acid	Fenofibric acid 45 mg/1	Capsule, Delayed releaseOral	Aurobindo Pharma Limited	59651-216